Ardana Bioscience acquired Europeptides from Degussa/Zentaris. Ardana will gain global rights to a proprietary formulation of the prostate cancer treatment Leuprorelin. The company will also gain European and North American rights to Teverelix for use in contraception and hormonal disorders.